Cloud-based User Platform Expanded To Support New Offerings
Bangalore and Glen Burnie, MD, January 14, 2013
Infosys, a global leader in consulting and technology, has partnered with NovaSom, Inc., the leader in home testing for obstructive sleep apnea (OSA), to significantly improve the efficiency of administering and analyzing results of home tests.
Infosys has designed an innovative cloud-based user portal, Meditrack®, on Salesforce.com to broaden the reach and efficiency of NovaSom’s diagnostic solution suite. The new portal provides physicians with a single, easy-to-use interface that speeds up the order-to-delivery of devices, processing of diagnostic data and management of insurance claims.
Meditrack® provides Web interfaces with third-party applications to access and analyze patient data immediately upon wireless receipt of the completed home sleep test. The portal, launched earlier this year, enables NovaSom to shorten the time from test completion to report generation by two days. This capability helps NovaSom’s sleep specialist customers deliver faster diagnoses to patients and speed their paths to treatment.
“Patients with OSA are at an increased risk of other chronic diseases. The innovative solution that we developed for NovaSom is helping OSA patients receive faster and better medical care, said Dheeshjith V.G., Senior Vice President and Global Head, Life Sciences at Infosys. “Leveraging our deep medical technology domain knowledge and harnessing the latest technical advancements has allowed us to enable NovaSom to facilitate rapid diagnostic and therapy cycles.”
The NovaSom diagnostic solution also leverages AccuSom®, the first and only FDA-cleared wireless home sleep testing device. With more than 18 million moderate to severe cases of OSA in the United States, NovaSom’s suite of accurate, cost-effective home sleep testing solutions is delivering new benefits to patients, health insurers, and specialty and primary care physicians.
In 2012, NovaSom expanded its product suite, launching AccuSom Deliver™, a customized turnkey solution allowing sleep specialists to incorporate high-quality, at-home sleep testing into their practices on a larger scale. AccuSom Safe Recovery™ was also launched this year, which leverages AccuSom’s wireless functionality to complete home sleep testing prior to surgery. The new portal from Infosys has helped NovaSom scale operations to meet the expanded solution portfolio more effectively. Sleep specialists, surgeons, and anesthesiologists can now develop a patient management plan that further minimizes the risk of adverse respiratory events and other OSA-related complications during and after surgery.
“A quicker OSA diagnosis is critical to helping sufferers get the therapy they need sooner, and we are achieving that goal with the help of Infosys,” said Richard Hassett, MD, Chief Executive Officer, NovaSom. “The customized MediTrack portal enables us to complete tests quickly and accurately. NovaSom’s cloud-based infrastructure allows us to partner with providers to improve access to care, reduce cost and address this undiagnosed epidemic.”
NovaSom, Inc. is the market leader in obstructive sleep apnea home testing, with the AccuSom Home Sleep Test, the first and only FDA-cleared wireless HST. The NovaSom home sleep testing technology and MediTrack portal have been shown to provide in-home, clinically equivalent diagnosis of OSA at a significantly reduced cost as compared to in-facility testing for uncomplicated, adult OSA. NovaSom’s home sleep tests are currently covered for more than 165 million Americans through partnerships with major health insurers.
NovaSom also offers comprehensive service programs that are utilized by payers, employers, primary care and sleep specialist physicians nationwide, that enable significant cost savings for OSA management. In an effort to combat the growing OSA epidemic, NovaSom also partners with sleep centers, enabling sleep specialists to offer clinically appropriate patients an alternative, convenient testing option, expanding access to diagnosis and treatment.
NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center & Telehealth Provider and is approved by CMS as an Independent Diagnostic Testing Facility. For more information, visit www.NovaSom.com.
Infosys partners with global enterprises to drive their innovation-led growth. That's why Forbes ranked Infosys 19th among the top 100 most innovative companies. As a leading provider of next-generation consulting, technology, and outsourcing solutions, Infosys helps clients in more than 30 countries realize their goals. Visit www.infosys.com and see how Infosys (NYSE: INFY), with its 150,000+ people, is Building Tomorrow's Enterprise® today.
Certain statements in this release concerning our future growth prospects are forward-looking statements, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2012 and on Form 6-K for the quarters ended December 31, 2011, June 30, 2012 and September 30, 2012. These filings are available at www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the company.
For further information, please contact: PR_Global@infosys.com